{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:25:14Z","timestamp":1791181514382,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T00:00:00Z","timestamp":1310601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0022-x","type":"journal-article","created":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T10:32:27Z","timestamp":1310553147000},"page":"2207-2211","source":"Crossref","is-referenced-by-count":13,"title":["Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases"],"prefix":"10.1007","volume":"29","author":[{"given":"Nada","family":"Suvajdzic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Djurdjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Perunicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roksanda","family":"Stojanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Novkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,14]]},"reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"E Zintzaras","year":"2005","unstructured":"Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases. Arch Intern Med. 2005;165:2337\u201344.","journal-title":"Arch Intern Med"},{"key":"22_CR2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/ard.2004.034504","volume":"64","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, et al. Non-Hodgkin lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1507\u20139.","journal-title":"Ann Rheum Dis"},{"key":"22_CR3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3816\/CLM.2008.n.009","volume":"8","author":"R Kaiser","year":"2008","unstructured":"Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87\u201393.","journal-title":"Clin Lymphoma Myeloma"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","volume":"98","author":"KE Smedby","year":"2006","unstructured":"Smedby KE, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma subtype. J Nat Cancer Inst. 2006;98:51\u201360.","journal-title":"J Nat Cancer Inst"},{"key":"22_CR5","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"KE Smedby","year":"2008","unstructured":"Smedby KE. et.al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029\u201338.","journal-title":"Blood"},{"key":"22_CR6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ncprheum0620","volume":"3","author":"A Hansen","year":"2007","unstructured":"Hansen A, Lipsky PE, Dorner T. B-cell lymphoprolifeartion in chronic inflamatory rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:561\u20139.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","volume":"15","author":"KE Smedby","year":"2006","unstructured":"Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15:2069\u201377.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"22_CR8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum. 2004;50:1740\u201351.","journal-title":"Arthritis Rheum"},{"key":"22_CR9","volume-title":"Pathology and genetics of tumours of hematopoietic and lymphoid tissue","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of hematopoietic and lymphoid tissue. World Health Organisation Classification of Tumours Lyon: IARC Press; 2001."},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Hematologica. 2009;94:1581\u20139.","journal-title":"Hematologica"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271\u20137.","journal-title":"Arthritis Rheum"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.1780360309","volume":"36","author":"C Vitali","year":"1993","unstructured":"Vitali C, et al. Preliminary classification criteria for Sj\u00f6gren\u2019s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36:340\u20137.","journal-title":"Arthritis Rheum"},{"key":"22_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"D Masi","year":"1980","unstructured":"Masi D, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"22_CR15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403\u20137.","journal-title":"N Engl J Med"},{"key":"22_CR17","first-page":"43","volume":"17","author":"JA Moormeier","year":"1990","unstructured":"Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin lymphomas. Semin Oncol. 1990;17:43\u201350.","journal-title":"Semin Oncol"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"T Lister","year":"1989","unstructured":"Lister T, et al. Report of the committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotsworld meeting. J Clin Oncol. 1989;7:1630\u20136.","journal-title":"J Clin Oncol"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"22_CR20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"M Shipp","year":"1993","unstructured":"Shipp M, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"22_CR21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Ce\u2032ligny","year":"2004","unstructured":"Solal-Ce\u2032ligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"22_CR22","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","volume":"111","author":"KE Smedby","year":"2008","unstructured":"Smedby KE, et al. Autoimmune disorders and risk of non Hodgkin\u2019s lymphoma subtypes: a pooled analysis within the Interlymph Consortium. Blood. 2008;111:4029\u201338.","journal-title":"Blood"},{"key":"22_CR23","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1200\/JCO.2010.29.2243","volume":"28","author":"O Landgren","year":"2010","unstructured":"Landgren O, Pfeiffer RM, Kristinsson SY, Bj\u00f6rkholm M. Survival patterns in patients with Hodgkin\u2019s lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol. 2010;28:5081\u20137.","journal-title":"J Clin Oncol"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","volume":"125","author":"LA Anderson","year":"2009","unstructured":"Anderson LA, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398\u2013405.","journal-title":"Int J Cancer"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1191\/096120301701548481","volume":"10","author":"Y Xu","year":"2001","unstructured":"Xu Y, Wiernik PH. Systemic lupus erythematosus and B-cell hematological malignancy. Lupus. 2001;10:841\u201350.","journal-title":"Lupus"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/rheumatology\/kel444","volume":"46","author":"S Bernatsky","year":"2007","unstructured":"Bernatsky S, et al. Hodgkin\u2019s lymphoma in systemic lupus erythematosus. Rheumatology. 2007;46:830\u20132.","journal-title":"Rheumatology"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ijc.11582","volume":"108","author":"Y Hoshida","year":"2003","unstructured":"Hoshida Y, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2003;108:443\u20139.","journal-title":"Int J Cancer"},{"key":"22_CR28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","volume":"48","author":"K Ekstr\u0151m","year":"2003","unstructured":"Ekstr\u0151m K, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48:963\u201370.","journal-title":"Arthritis Rheum"},{"key":"22_CR29","unstructured":"Lin AY, Tucker MA (1998) Epidemiology of Hodgkin\u2019s disease and Non-Hodgkin\u2019s lymphomas. In: Canellos GP, Lister TA, Sklar JR. The lymphomas. 1st ed. Philadelphia: W.B. Saunders Company, pp 43\u201361."},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","volume":"24","author":"TR Mikuls","year":"2006","unstructured":"Mikuls TR, et al. Prospective study of survival outcomes in non-Hodgkin\u2019s lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006;24:1597\u2013602.","journal-title":"J Clin Oncol"},{"key":"22_CR31","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10067-006-0532-7","volume":"26","author":"JK King","year":"2007","unstructured":"King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin\u2019s lymphoma (NHL). Clin Rheumatol. 2007;26:1491\u20134.","journal-title":"Clin Rheumatol"},{"key":"22_CR32","first-page":"47","volume":"28","author":"TM Dawson","year":"2001","unstructured":"Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate and lymphoma in patients with rheumatoid arthritis and primary Sj\u0151gren\u2019s syndrome: case series. J Rheumatol. 2001;28:47\u201353.","journal-title":"J Rheumatol"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"E Theander","year":"2006","unstructured":"Theander E, et al. Lymphoma and other malignancies in primary Sj\u0151gren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796\u2013803.","journal-title":"Ann Rheum Dis"},{"key":"22_CR34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, et al. Association of chronic inflamation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheumatol. 2006;54:692\u2013701.","journal-title":"Arthritis Rheumatol"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/aje\/kwi341","volume":"162","author":"EA Engels","year":"2005","unstructured":"Engels EA, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin\u2019s lymphomas: a case-control study. Am J Epidemiol. 2005;162:1153\u201361.","journal-title":"Am J Epidemiol"},{"key":"22_CR36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.11144","volume":"48","author":"E Baecklund","year":"2003","unstructured":"Baecklund E, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 2003;48:1543\u201350.","journal-title":"Arthritis Rheum"},{"key":"22_CR37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2008.096925","volume":"69","author":"K Hellgren","year":"2010","unstructured":"Hellgren K, et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case\u2013control study. Ann Rheum Dis. 2010;69:654\u20139.","journal-title":"Ann Rheum Dis"},{"key":"22_CR38","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","volume":"99","author":"X Mariette","year":"2002","unstructured":"Mariette X, et al. Lymphoma in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909\u201315.","journal-title":"Blood"},{"key":"22_CR39","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","volume":"42","author":"M Voulgarelis","year":"1999","unstructured":"Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sj\u0151gren\u2019s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action of Sj\u0151gren\u2019s syndrome. Arthritis Rheum. 1999;42:1765\u201372.","journal-title":"Arthritis Rheum"},{"key":"22_CR40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","volume":"40","author":"J Cibere","year":"1997","unstructured":"Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997;40:1580\u20136.","journal-title":"Arthritis Rheum"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0022-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T19:32:13Z","timestamp":1560367933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0022-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]}}}